Expedite protocol for construction of chiral regioselectively N-protected monosubstituted piperazine, 1,4-diazepane, and 1,4-diazocane building blocks

Journal of Organic Chemistry

Volumn 74, Issue 15, 2009, Pages 5652-5655

  Crestey, François ^a   Witt, Matthias ^b   Jaroszewski, Jerzy W ^a   Franzyk, Henrik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BRUKER DALTONIK GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ALCOHOLS; AMINOLYSIS; AZIRIDINES; BUILDING BLOCK; CHEMICAL EQUATIONS; CHROMATOGRAPHIC PURIFICATION; MITSUNOBU CYCLIZATION; SHORT REACTION TIME; SOLUTION PHASE SYNTHESIS; STEP SEQUENCES;

ALCOHOLS; AMINES; SYNTHESIS (CHEMICAL);

AMINATION;

1,4 DIAZEPANE; 1,4 DIAZOCANE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINOLYSIS; ARTICLE; CHIRALITY; CYCLIZATION; OLIGOMERIZATION; RING OPENING; SOLID PHASE SYNTHESIS; STEREOCHEMISTRY;

AZEPINES; AZIRIDINES; MOLECULAR STRUCTURE; PIPERAZINES; STEREOISOMERISM;

EID: 68049108398     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo900441s     Document Type: Article

References (55)

1. Lu, S.; Zhang, Y.; Liu, J.; Zhao, C.; Liu, W.; Xi, R. J. Agric. Food. Chem. 2006, 54, 6995-7000.
2. Madrid, P. B.; Polgar, W. E.; Toll, L.; Tanga, M. J. Bioorg. Med. Chem. Lett. 2007, 17, 3014-3017.
3. Leopoldo, M.; Lacitiva, E.; Colabufo, N. A.; Contino, M.; Berardi, F.; Perrone, R. J. Med. Chem. 2005, 48, 7919-7922.
4. Askin, D.; Eng, K. K.; Rossen, K.; Purick, R. M.; Welss, K. M.; Volante, R. P.; Reider, P. J. Tetrahedron Lett. 1994, 35, 673-676.
5. Su, J.; Tang, H.; McKittrick, B. A.; Burnett, D. A.; Zang, H.; Smith-Torhan, A.; Fawzi, A.; Lachowicz, J. Bioorg. Med. Chem. Lett. 2006, 16, 4548-4553.
6. For tetrazepam, see: (a) Piek, T.; van Weeren-Kramer, J.; van Wilgenburg, H.; Zeegers, A.; Leeuwin, R. S. Neurosci. Res. Comm. 2001, 28, 85-93.
7. For dilazep, see: (b) Nakamoto, H.; Ogasawara, Y.; Kajiya, F. Hypertens. Res. 2008, 31, 315-324.
8. For chlorpromazine, see: (c) Bailey, A. M.; Paulsen, I. T.; Piddock, L. V. J. Antimicrob. Agents Chemother. 2008, 52, 3604-3611.
9. Oppong, K. A.; Ellis, C. D.; Laufersweiler, M. C.; O'Neil, S. V.; Wang, Y.; Soper, D. L.; Baize, M. W.; Wos, J. A.; De, B.; Bosch, G. K.; Fancher, A. N.; Lu, W.; Suchanek, M. K.; Wang, R. L.; Demuth, T. P. Jr. Bioorg. Med. Chem. Lett. 2005, 15, 4291-4294.
10. Audouze, K.; Nielsen, E. Oe.; Olsen, G. M.; Ahring, P.; Joergensen, T. D.; Peters, D.; Liljefors, T.; Balle, T. J. Med. Chem. 2006, 49, 3159-3171.
11. Gellerman, G.; Hazan, E.; Kovaliov, M.; Albeck, A.; Shatzmiller, S. Tetrahedron 2009, 65, 1389-1396 and references cited herein.
12. (a) Gao, H.; Renslo, A. R. J. Org. Chem. 2007, 72, 8591-8592.
13. For synthesis of racemic compounds, see: (b) Clark, R. B.; Elbaum, D. G. Tetrahedron 2007, 63, 3057-3065.
14. (a) Maity, P.; König, B. Org. Lett. 2008, 10, 1473-1476.
15. (b) Lencina, C. L.; Dassonville-Klimpt, A.; Sonnet, P. Tetrahedron: Asymmetry 2008, 19, 1689-1697.
16. (c) Li, H.-Y.; Morisseau, C.; Hammock, B. D.; Long, Y.-Q. Bioorg. Med. Chem. 2006, 14, 6586-6592.
17. (d) Viso, A.; Pradilla, R. F.; Flores, A.; Garcia, A.; Tortosa, M.; Lopez-Rodrigues, M. L. J. J. Org. Chem. 2006, 71, 1442-1448.
18. (e) Franceschini, N.; Sonnet, P.; Guillaume, D. Org. Biomol. Chem. 2005, 3, 787-793.
19. (f) Dinsmore, C. J.; Beshore, D. C. Tetrahedron 2002, 58, 3297-3312.
20. (g) Dinsmore, C. J.; Beshore, D. C. Org. Prep. Proced. Int. 2002, 34, 367-404.
21. (h) Pohlmann, A.; Schanen, V.; Guillaume, D.; Quirion, J. C.; Husson, H. P. J. Org. Chem. 1997, 62, 1016-1022.
22. Berkheij, M.; van der Sluis, L.; Sewing, C.; den Boer D. J.; Terpstra, J. W.; Hiemstra, H.; Iwena Bakker, W. I.; van den Hoogenband, A.; van Maarseveen, J. H. Tetrahedron Lett. 2005, 46, 2369-2371.
23. Hidaka, H.; Nishio, M.; Sumi, K. U.S. 08064681, 2008; Chem. Abstr. 2008, 148, 331572.
24. For synthesis of tetraaza macrocycles bearing a chiral diazepane ring, see: Kang, S.-G.; Choi, J.-S.; Nam, K.; Chun, H.; Kim, K. Inorg. Chim. Acta 2004, 357, 2783-2790.
25. (a) Bedürftig, S.; Wünsch, B. Eur. J. Med. Chem. 2009, 44, 519-525.
26. (b) Keenan, T. P.; Kaplan, A. P. US 07203124, 2007; Chem. Abstr. 2007, 147, 323014.
27. (c) Revesz, L.; Bollbuck, B.; Buhl, T.; Eder, J.; Esser, R.; Feifel, R.; Heng, R.; Hiestand, P.; Jachez-Demange, B.; Loetscher, P.; Sparrer, H.; Schlapbach, A.; Waelchli, R. Bioorg. Med. Chem. Lett. 2005, 15, 5160-5164.
28. Li, D.; Hall, D. G. Tetrahedron: Asymmetry 2005, 16, 1733-1736.
29. (a) Ottesen, L. K.; Olsen, C. A.; Witt, M.; Jaroszewski, J. W.; Franzyk, H. Chem. - Eur. J. 2009, 15, 2966-2978.
30. (b) Crestey, F.; Ottesen, L. K.; Jaroszewski, J. W.; Franzyk, H. Tetrahedron Lett. 2008, 49, 5890-5893.
31. (c) Crestey, F.; Witt, M.; Frydenvang, K.; Stærk, D.; Jaroszewski, J. W.; Franzyk, H. J. Org. Chem. 2008, 73, 3566-3569.
32. (d) Olsen, C. A.; Christensen, C.; Nielsen, B.; Mohamed, F. M.; Witt, M.; Clausen, R. P.; Kristensen, J. L.; Franzyk, H.; Jaroszewski, J. W. Org. Lett. 2006, 8, 3371-3374.
33. For synthesis of a disubstituted piperazine from an aziridine, see: Letavic, M. A.; Barberia, J. T.; Carty, T. J.; Hardink, J. R.; Liras, J.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Noe, M. C.; Reeves, L. M.; Snow, S. L.; Stam, E. J.; Sweeney, F. J.; Vaughn, M. L.; Yu, C. H. Bioorg. Med. Chem. Lett. 2003, 13, 3243-3246.
34. For complete data on aziridine building blocks 2a-e, see ref 17c. For further details on aziridine 2f, see the Supporting Information.
35. To avoid possible repeated ring-opening of aziridine building blocks by the secondary amine formed in the reaction, a large excess of the amino alcohol was used during the first step of the sequential protocol.
36. For a recent review on Fukuyama-Mitsunobu reactions, see: Golantsov, N. E.; Karchava, A. V.; Yurovskaya, M. A. Chem. Heterocycl. Compd. 2008, 44, 263-294.
37. When diethyl azodicarboxylate (DEAD) was employed in this Fukuyama-Mitsunobu reaction, a similar yield was obtained. Cf.: Kümmerle, A. E. Synlett 2008, 2373-2374.
38. For recent examples on Fukuyama-Mitsunobu reactions, see: (a) Nielsen, T. E.; Schreiber, S. L. Angew. Chem., Int. Ed. 2008, 47, 48-56.
39. (b) Demmer, O.; Dijkgraaf, I.; Schottelius, M.; Wester, H.-J.; Kessler, H. Org. Lett. 2008, 10, 2015-2018.
40. (c) Leach, S. G.; Cordier, C. J.; Morton, D.; McKiernan, G. J.; Wariner, S.; Nelson, A. J. Org. Chem. 2008, 73, 2753-2759.
41. (d) Zapf, C. W.; Del Valle, J. R.; Goodman, M. Bioorg. Med. Chem. Lett. 2005, 15, 4033-4036.
42. For complete optical rotation data, see the Supporting Information.
43. For recent examples on Fukuyama-Mitsunobu and Mitsunobu reactions with diols, see: (a) Valeur, E.; Roche, D. Tetrahedron Lett. 2008, 49, 4182-4185.
44. (b) García-Delgado, N.; Riera, A.; Verdaguer, X. Org. Lett. 2007, 9, 635-638.
45. (c) Wilkinson, M. C.; Bell, R.; Landon, R.; Nikiforov, P. O.; Walker, A. J. Synthesis 2006, 2151-2153.
46. (d) Hovinen, J.; Sillanpää, R. Tetrahedron Lett. 2005, 46, 4387-4389.
47. For a recent investigation on SPS of medium-sized as well as very large rings, see: Bisegger, P.; Manov, N.; Bienz, S. Tetrahedron 2008, 64, 7531-7536.
48. Kan, T.; Fujiwara, A.; Kobayashi, H.; Fukuyama, T. Tetrahedron 2002, 58, 6267-6276.
49. Fukuyama, T.; Jow, C.-K.; Cheung, M. Tetrahedron Lett. 1995, 36, 6373-6374.
50. For recent examples of denosylation, see: (a) Kinderman, S. S.; Wekking, M. M. T.; van Maarseveen, J. H.; Schoemaker, H. E.; Hiemstra, H.; Rutjes, F. P. J. T. J. Org. Chem. 2005, 70, 5519-5527.
51. (b) Olsen, C. A.; Witt, M.; Jaroszewski, J. W.; Franzyk, H. Synlett 2004, 473-476.
52. (c) Barluenga, J.; Trincado, M.; Rubio, E.; Gonzales, J. M. J. Am. Chem. Soc. 2004, 126, 4100-4101.
53. (d) Elango, S.; Yan, T.-H. J. Org. Chem. 2002, 67, 6954-6959.
54. 13C NMR signals were doubled indicating the presence of two rotamers involving the carbamate group. For further details, see the Supporting Information.
55. For further details, see the Experimental Section.